<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Instant glucose and intravenous dextrose: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Instant glucose and intravenous dextrose: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Instant glucose and intravenous dextrose: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11483" href="/d/html/11483.html" rel="external">see "Instant glucose and intravenous dextrose: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13222" href="/d/html/13222.html" rel="external">see "Instant glucose and intravenous dextrose: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F158911"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Gluco to Go 15 [OTC];</li>
<li>Gluco To Go [OTC];</li>
<li>Glucose Nursette [OTC];</li>
<li>Glutol [OTC];</li>
<li>Glutose 5 [OTC];</li>
<li>Good Start 5% Glucose Water [OTC];</li>
<li>Insta-Glucose [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866569"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Glucodex</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F158922"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote, Hypoglycemia;</li>
<li>
                        Intravenous Nutritional Therapy</li></ul></div>
<div class="block doa drugH1Div" id="F158912"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f0f08c28-c232-4eaf-b74b-04939d962ca9">Calcium channel blocker or beta-blocker overdose/toxicity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker or beta-blocker overdose/toxicity (adjunctive agent) (off-label use): Note:</b> For use <b>only </b>as an adjuvant component of high-dose insulin therapy (HDIT). Optimal dosage regimen has not been determined; HDIT is used for patients who are refractory to initial therapies (eg, atropine, calcium, vasopressors). Monitor blood glucose and electrolytes frequently, especially at the initiation of therapy. Use of concentrated dextrose solutions may help to avoid fluid overload (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-30141827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-30141827'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients <b>with</b> existing hypoglycemia:</i>
<b>Note: </b>Correct relative hypoglycemia (baseline blood glucose &lt;200 mg/dL) prior to initiation of HDIT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-30141827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29452919','lexi-content-ref-21563902','lexi-content-ref-30141827'])">Ref</a></span>); some experts recommend a lower baseline blood glucose (&lt;150 mg/dL) at which to correct hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barrueto.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barrueto.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 25 g (50 mL D50W) as a single bolus dose followed by a continuous infusion of 0.5 g/kg/hour when HDIT is initiated; titrate dextrose to maintain blood glucose concentration &gt;100 mg/dL. Hold dextrose for blood glucose concentration ≥200 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30141827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30141827'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients <b>without </b>existing hypoglycemia: </i>Initiate a continuous infusion of 0.5 g/kg/hour when HDIT is initiated; titrate dextrose infusion to maintain blood glucose concentration &gt;100 mg/dL. Hold dextrose for blood glucose concentration ≥200 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30141827']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30141827'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a56630d-e918-409b-a2e9-9be39bbc56cb">Glucose tolerance test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glucose tolerance test (diagnostic test for diabetes):</b> Glutol: <b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>One-step:</i> 75 g as single dose to a <b>fasting patient;</b> assess plasma glucose 2 hours after dose in nonpregnant patients or 1 and 2 hours after dose in pregnant patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Two-step:</i> Pregnant patients:</p>
<p style="text-indent:-2em;margin-left:6em;">First step: 50 g as a single dose to a <b>nonfasting patient</b>; assess plasma glucose 1 hour after dose; if plasma glucose levels ≥130 mg/dL proceed to 100 g oral glucose tolerance test. <b>Note:</b> Cutoffs of ≥135 or ≥140 mg/dL have also been recommended; increased sensitivity and decreased specificity have been associated with use of a lower cutoff (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Second step: 100 g as a single dose to a <b>fasting patient; </b>assess plasma glucose at 1, 2, and 3 hours after dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.3'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="637f3b98-5df7-446f-8c61-563a0b944ec9">Hyperkalemia, severe/emergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, severe/emergent (adjunctive agent) (off-label use): Note:</b> Used as an adjunct to insulin therapy. Consider omitting dextrose from regimen if blood glucose is ≥250 mg/dL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31084947'])">Ref</a></span>). Practice may vary; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 25 to 50 g dextrose over 5 minutes; only administer along with separate administration of IV insulin (eg, regular insulin); repeat as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2266671','lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2266671','lexi-content-ref-31084947'])">Ref</a></span>). After initial dose of dextrose, some experts administer 10% dextrose continuous IV infusion at 50 to 100 mL/hour for ~5 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1','lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1','lexi-content-ref-31084947'])">Ref</a></span>). <b>Note:</b> Monitor blood glucose every hour for up to 6 hours after insulin has been administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1','lexi-content-ref-31084947']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1','lexi-content-ref-31084947'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c029be15-9190-449e-9e36-9f1434c41569">Hypernatremia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypernatremia (off-</b>
<b>label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use caution in patients with elevated intracranial pressure. Most patients with hypernatremia have chronic hypernatremia, including those who present with acute concerns (eg, change in mental status). Dosing requires individualization based on serum sodium levels and clinical factors (eg, presence of symptoms, duration of hypernatremia, volume status). Approach below provides a guide to<b> initial</b> therapy based on estimation of water deficit and appropriate rates of correction. Address sources of ongoing free water loss and reversible causes of hypernatremia. Patients with concurrent medical conditions may need additional therapies (eg, hypovolemic patients may require additional isotonic fluid; patients with diabetes insipidus may require desmopressin). Refer to institution-specific protocols where available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-Rajajee.1','lexi-content-ref-Sterns.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-Rajajee.1','lexi-content-ref-Sterns.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>
<i>Chronic (&gt;48 hours or unknown duration):</i></b>
<b>
<i></i></b>
<b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Goal rate of serum sodium decrease is ≤0.5 mEq/L per hour (~10 mEq/L/24 hours; no more than 12 mEq/L/24 hours). In clinically stable, asymptomatic patients, may consider enteral correction of hypernatremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-22762930','lexi-content-ref-Sterns.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-22762930','lexi-content-ref-Sterns.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>5% dextrose: IV:</b> Initial: ~1.35 mL/kg/hour up to a maximum of 150 mL/hour; add ongoing hourly water losses (eg, urinary or GI) to initial infusion rate, if known. Adjust rate based on repeat serum sodium levels (eg, every 4 to 6 hours initially, then every 12 to 24 hours after target rate of sodium decrease is attained) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sterns.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sterns.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute (</i></b>
<b>
<i>≤48 hours in duration):</i></b>
<b>
<i></i></b>
<b></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>For use in patients with confirmed hypernatremia ≤48 hours in duration (eg, diabetes insipidus with abrupt cessation of water intake, acute salt poisoning). Goal rate of initial serum sodium decrease is ≤1 to 2 mEq/L per hour to reach a serum sodium of 140 mEq/L in &lt;24 hours. In patients with hypernatremia secondary to correction of severe hyperglycemia, consider an alternative source of free water (eg, sodium chloride 0.45%); if treating hypernatremia secondary to correction of severe hyperglycemia in younger patients (eg, ≤40 years of age), some experts correct serum sodium more slowly (ie, with chronic regimen above) to prevent cerebral edema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16085929','lexi-content-ref-Sterns.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16085929','lexi-content-ref-Sterns.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>5% dextrose: IV:</b> Initial: 3 to 6 mL/kg/hour up to a maximum of 666 mL/hour; add ongoing hourly water losses (eg, urinary or GI) to initial infusion rate, if known. Adjust dose based on frequent serum sodium monitoring (eg, every 1 to 3 hours). When serum sodium is ≤145 mEq/L, reduce rate to ~1 mL/kg/hour, monitor serum sodium every 2 to 4 hours, and continue until serum sodium reaches 140 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sterns.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sterns.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cae6678c-7f9f-417f-b0d5-a66ff7ecfced">Hypoglycemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 10 to 25 g (20 to 50 mL of 50% solution); repeat as needed in severe cases.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> The Society of Critical Care Medicine suggests that blood glucose &lt;70 mg/dL (or &lt;100 mg/dL in neurologic injury patients) be treated immediately by discontinuing insulin therapy (if receiving) and administering 10 to 20 g (20 to 40 mL of 50% solution) IV; repeat blood glucose measurement in 15 minutes with repeat dextrose administration as necessary; avoid overcorrection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23164767']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23164767'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 15 to 20 g as a single dose; may repeat in 15 minutes if hypoglycemia persists. Once plasma glucose returns to normal, a meal or snack should be consumed to prevent recurrence of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.3'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F53733755"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dextrose is excreted by the kidney, and closer monitoring for adverse effects may be warranted in patients with renal impairment.</p></div>
<div class="block doha drugH1Div" id="F53733756"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F3062956"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F158919"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13222" href="/d/html/13222.html" rel="external">see "Instant glucose and intravenous dextrose: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cae6678c-7f9f-417f-b0d5-a66ff7ecfced">Hypoglycemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypoglycemia: Note:</b> Doses may be repeated in severe cases:</p>
<p style="text-indent:-2em;margin-left:4em;">IV, Intraosseous:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children: Dextrose 25% solution: IV, Intraosseous: 0.5 to 1 g/kg/dose (2 to 4 mL/kg/dose of 25% solution); maximum dose: 25 g/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: Dextrose 50% solutions: IV, Intraosseous: 0.5 to 1 g/kg/dose (1 to 2 mL/kg/dose of 50% solution); maximum dose: 25 g/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Children and Adolescents: Oral: 0.3 g/kg as a single dose; usual maximum dose: 15 to 20 g/dose; repeat in 15 minutes if hypoglycemia persists; smaller doses (eg, 5 to 10 g) could be considered for patients on automated insulin delivery to help avoid rebound hyperglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.3','lexi-content-ref-36537534']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.3','lexi-content-ref-36537534'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c38c267b-5990-4874-9850-e45ba5771599">Hyperkalemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, treatment:</b> Limited data available: <b>Note:</b> Experts suggest using a ratio of 1 unit of insulin for every 5 g of dextrose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lynch.1','lexi-content-ref-Wilkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lynch.1','lexi-content-ref-Wilkins.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 0.5 to 1 g/kg/dose combined with regular insulin over 15 to 30 minutes; dose may be repeated; in some cases, a continuous IV infusion may be necessary. In adults, the usual initial dose of dextrose is 25 to 50 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956228','lexi-content-ref-21181208','lexi-content-ref-Lynch.1','lexi-content-ref-21920871']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956228','lexi-content-ref-21181208','lexi-content-ref-Lynch.1','lexi-content-ref-21920871'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f7203a-e10c-47ac-b028-3c148b2d3e81">Parenteral nutrition</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition:</b> Dextrose component (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASPEN.2','lexi-content-ref-Corkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASPEN.2','lexi-content-ref-Corkins.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: IV: Initial: 6 to 8 <b>mg</b>/kg/minute; usual daily increase: 1 to 2 <b>mg</b>/kg/minute as tolerated; usual goal: 10 to 14 <b>mg</b>/kg/minute; maximum daily rate: 18 <b>mg</b>/kg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≤10 years: IV: Initial: 3 to 6 <b>mg</b>/kg/minute; usual daily increase: 1 to 2 <b>mg</b>/kg/minute; usual goal as tolerated: 8 to 10 <b>mg</b>/kg/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;10 years and Adolescents: IV: Initial: 2.5 to 3 <b>mg</b>/kg/minute; usual daily increase: 1 to 2 <b>mg</b>/kg/minute as tolerated; usual goal: 5 to 6 <b>mg</b>/kg/minute.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a56630d-e918-409b-a2e9-9be39bbc56cb">Glucose tolerance test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glucose</b>
<b> tolerance test (diagnostic test for diabetes):</b> Oral liquid: Children and Adolescents: Oral: 1.75 g/kg as a single dose; maximum dose: 75 g/dose; assess plasma glucose 2 hours after dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30093549','lexi-content-ref-36537527']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30093549','lexi-content-ref-36537527'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F58219128"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dextrose is excreted by the kidney, and closer monitoring for adverse effects may be warranted in patients with renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F58219129"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F158889"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Localized phlebitis, phlebitis, venous thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Confusion, loss of consciousness</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration, glycosuria, hyperglycemia, hyperosmolar syndrome, hypervolemia, hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local pain</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary edema</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Hypersensitivity reaction (including anaphylaxis)</p></div>
<div class="block coi drugH1Div" id="F158901"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Injectable: Hypersensitivity to dextrose, corn or corn products, or any component of the formulation; hypertonic solutions in patients with intracranial or intraspinal hemorrhage; delirium tremens (if dehydrated); severe dehydration; clinically significant hyperglycemia; anuria; hepatic coma; dextrose solutions without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur. Contraindications may vary by product (also refer to manufacturer's labeling).</p></div>
<div class="block war drugH1Div" id="F158887"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Dextrose 10% may be an irritant. Concentrated IV dextrose (&gt;10%) may be an irritant or a vesicant. Higher concentration (higher osmolarity) is associated with a higher risk. Ensure proper catheter or needle position prior to and during infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatobiliary effects: Hepatobiliary disorders (eg, cholecystitis, cholelithiasis, cholestasis, cirrhosis, hepatic steatosis, fibrosis) may occur in patients without liver disease who receive parenteral nutrition and may lead to hepatic failure. Increase in blood ammonia levels and hyperammonemia may also occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperglycemia or hyperosmolar hyperglycemic state: Use of dextrose infusions with impaired glucose intolerance may worsen hyperglycemia. Administration of dextrose at a rate exceeding the patient's utilization rate may lead to hyperglycemia, coma, and death. Patients with underlying CNS disease and renal impairment may be at greater risk of developing hyperosmolar hyperglycemic state.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity/infusion reactions, including anaphylaxis, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Administration of IV dextrose solutions (particularly high concentrations) without the addition of potassium may result in significant hypokalemia; monitor closely and/or add potassium to dextrose solutions for patients with adequate renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyponatremia/sodium disorders: Administration of low sodium or sodium-free IV dextrose solutions may result in excessive reduction of serum sodium, significant hyponatremia, or water intoxication. Risk is increased in pediatric patients, older adults, postoperative patients, and those with psychogenic polydipsia. Avoid dextrose injection in patients with or at risk for hyponatremia; if used, monitor serum sodium concentration. Use high-volume infusion with caution in patients with cardiac or pulmonary failure and in patients with nonosmotic vasopressin release (ie, syndrome of inappropriate antidiuretic hormone secretion) due to the risk of hospital-acquired hyponatremia. Rapid correction of sodium disorders is potentially dangerous (eg, may cause cerebral edema or osmotic demyelination syndrome) (Kraft 2005; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Patients requiring parenteral nutrition may be at high risk of infection, including sepsis. Risk of infection is increased with malnutrition, hyperglycemia exacerbated by dextrose infusion, or catheters required for administration. Proper aseptic technique should be followed; monitor for signs of early infection. Patients with diabetes are at a greater risk of developing catheter-related infections compared with nondiabetic patients (McMahon 1996).</p>
<p style="text-indent:-2em;margin-left:4em;">• Parenteral nutrition-associated liver disease: Has been reported in patients receiving parenteral nutrition for extended periods of time, especially preterm infants, and can present as cholestasis or steatohepatitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Refeeding syndrome: Refeeding severely undernourished patients may result in refeeding syndrome (eg, intracellular shift of potassium, phosphorus, and magnesium as the patient becomes anabolic); thiamine deficiency and fluid retention may also develop. Carefully monitor severely undernourished patients and slowly increase dextrose and other nutrient intakes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; hyperglycemia and glycosuria may be functions of the rate of administration of dextrose; to minimize these effects, reduce the rate of infusion; addition of insulin may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: The use of dextrose with insulin for the treatment of hyperkalemia achieves a rapid reduction in serum potassium concentrations by redistributing serum potassium intracellularly; however, this effect is transient (lasts up to 2 hours) and does not remove potassium body stores. Other therapies can be used to increase potassium elimination (eg, sodium polystyrene sulfonate, hemodialysis) (Elliott 2010; Khilnani 1992; Kraft 2005).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary edema: Use with caution in patients with pulmonary edema; these patients are susceptible to excessive fluid accumulation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; may be at risk of electrolyte and fluid volume overload and of developing hyperosmolar hyperglycemic state. Parenteral product may contain aluminum, which may accumulate following prolonged administration in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Very low birth weight infants: Excessive or rapid dextrose administration in very low birth weight infants has been associated with increased serum osmolality and possible intracerebral hemorrhage.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral dosage forms: In patients with impaired consciousness, oral dextrose administration may increase the risk of aspiration; use only when no alternatives (eg, parenteral dextrose, glucagon) are available (Desimone 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Precipitates: Periodically inspect solution, infusion set, and catheter for precipitates. Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress have been reported (some fatal). If signs of pulmonary distress occur, stop the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abrupt withdrawal: Rebound hypoglycemia may occur when a concentrated dextrose infusion is abruptly withdrawn.</p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Hypertonic solutions (&gt;10%) may cause thrombosis if infused via peripheral veins; administer hypertonic solutions via a central venous catheter.</p></div>
<div class="block foc drugH1Div" id="F158895"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Gel, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gluco to Go 15: 40% (37.5 g) [contains methylparaben, propylparaben; lemon flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glutose 5: 40% (12.5 g) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Insta-Glucose: 40% dextrose (77.4% total carbohydrate) (31 g) [contains fd&amp;c red #40 (allura red ac dye), methylparaben, propylparaben, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glutol: 100 g/180 mL (180 mL) [lemon flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/mL (10 mL); 5% (25 mL, 50 mL, 100 mL, 250 mL, 500 mL, 1000 mL); 10% (250 mL, 500 mL, 1000 mL); 40% (500 mL); 70% (2000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5% (100 mL, 150 mL, 250 mL, 500 mL, 1000 mL); 10% (250 mL, 500 mL, 1000 mL); 20% (500 mL); 30% (500 mL); 50% (50 mL, 500 mL); 70% (500 mL, 2000 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glucose Nursette: 5% (59 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Good Start 5% Glucose Water: 5% (88.7 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Chewable, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Gluco To Go: 4 g [fat free, gluten free, sodium free; contains fd&amp;c red #40(allura red ac)aluminum lake; raspberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 g [DSC]</p></div>
<div class="block geq drugH1Div" id="F158884"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F16323104"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Chewable</b> (Gluco To Go Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 g (per each): $0.12</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Gluco to Go 15 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40% (per gram): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Glutose 15 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40% (per gram): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Glutose 5 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40% (per gram): $0.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Gel</b> (Insta-Glucose Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">77.4% (per gram): $0.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $0.05 - $0.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $0.01 - $0.02</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20% (per mL): $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30% (per mL): $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40% (per mL): $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50% (per mL): $0.10 - $0.40</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">70% (per mL): $0.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Glucose Nursette Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $0.03</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Good Start 5% Glucose Water Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5% (per mL): $0.02</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866570"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Glucodex: 250 mg/mL (300 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5% (10 mL, 25 mL, 50 mL, 100 mL, 150 mL, 250 mL, 500 mL, 1000 mL); 10% (250 mL, 500 mL, 1000 mL); 20% (500 mL, 1000 mL); 40% ([DSC]); 50% (50 mL, 500 mL, 1000 mL, 2000 mL); 70% (500 mL, 1000 mL, 2000 mL, 3000 mL)</p></div>
<div class="block adm drugH1Div" id="F158898"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Must be swallowed to be absorbed; buccal absorption has been shown to be minimal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-691147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-691147'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Injectable is not for SUBQ or IM administration; concentrated dextrose solutions for peripheral venous administration must be diluted (maximum concentration: 12.5%); in emergency situations only, 25% and 50% dextrose have been used peripherally; for direct IV infusion, infuse at a maximum rate of 200 mg/kg over 1 minute; continuous infusion rates vary with tolerance and range from 4.5 to 15 mg/kg/minute. Refer to indication-specific infusion rates in dosing for detailed recommendations.</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">Dextrose 10% may be an irritant. Concentrated IV dextrose (&gt;10%) may be an irritant or a vesicant. Higher concentration (higher osmolarity) is associated with a higher risk. Ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:0em;margin-left:2em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hyaluronidase:</i></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Dextrose 10% to &lt;50%: Intradermal or SUBQ:</b> Inject a total of hyaluronidase 1 mL (15 units/mL) as 5 separate 0.2 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer IV through infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Dextrose 50%: </b>
<b>SUBQ</b>
<b>:</b> Inject a total of hyaluronidase 1 mL (150 units/mL) as 5 separate 0.2 mL injections administered along the leading edge of erythema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20159411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20159411'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612527"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be swallowed or administered via buccal or sublingual routes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30973639']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30973639'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Buccal: Neonate: Dry mouth with gauze; massage gel into buccal mucosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33507929','lexi-content-ref-24075361']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33507929','lexi-content-ref-24075361'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: For IV administration only, not SUBQ or IM. Maximum concentration for peripheral administration is 12.5% and for central administration is 25% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1'])">Ref</a></span>); although generally not recommended, in emergency situations, IV bolus doses of dextrose 25% have been used peripherally in infants and children and dextrose 50% has been used peripherally in adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Continuous infusion rates vary with tolerance and range from 4 to 14 <b>mg</b>/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASPEN.2','lexi-content-ref-24052783']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASPEN.2','lexi-content-ref-24052783'])">Ref</a></span>); neonates with hyperinsulinemia may require up to 15 to 20 <b>mg</b>/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3302901']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3302901'])">Ref</a></span>); a more rapid administration of 0.2 g/kg bolus of D10W over ≥1 minute for treatment of hypoglycemia has been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Barrero-Castillero.1','lexi-content-ref-Garg.1','lexi-content-ref-7400902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Barrero-Castillero.1','lexi-content-ref-Garg.1','lexi-content-ref-7400902'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Dextrose 10% may be an irritant. Concentrated IV dextrose (&gt;10%) may be an irritant or a vesicant; higher concentration (higher osmolarity) is associated with a higher risk. Ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F158897"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Hypoglycemia: Treatment of hypoglycemia</p>
<p style="text-indent:-2em;margin-left:4em;">Glucose tolerance test (Glutol): Oral glucose tolerance test for diagnosis of diabetes mellitus</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intravenous: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>5% and 10% solutions:</i> Fluid replacement/calories: Provision of calories and/or fluid replacement</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>25% (hypertonic) solution:</i> Hypoglycemia: Treatment of acute symptomatic episodes of hypoglycemia in infants and children to restore depressed blood glucose levels</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>50% (hypertonic) solution: </i> Hyperinsulinemia, insulin shock: Treatment of insulin-induced hypoglycemia (hyperinsulinemia or insulin shock)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>≥10% solutions:</i> Nutritional support: Infusion after admixture with other intravenous nutrients (eg, amino acids, fat emulsion) for nutritional support</p></div>
<div class="block off-label drugH1Div" id="F28843783"><span class="drugH1">Use: Off-Label: Adult</span><p>Calcium channel blocker or beta-blocker overdose/toxicity (adjunctive agent); Hyperkalemia, severe/emergent; Hypernatremia</p></div>
<div class="block mst drugH1Div" id="F158927"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Glutose may be confused with Glutofac</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (hypertonic solutions ≥20%) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Inappropriate use of low sodium or sodium-free intravenous fluids (eg D<sub>5</sub>W, hypotonic saline) in pediatric patients can lead to significant morbidity and mortality due to hyponatremia (ISMP 2009).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299170"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F158890"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F14207749"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Appropriate use of dextrose injection would not be expected to cause adverse developmental outcomes to the fetus when used during pregnancy. Maternal hyperglycemia or malnutrition may be associated with adverse pregnancy outcomes.</p>
<p style="text-indent:0em;margin-top:2em;">In patients with nausea and vomiting of pregnancy who cannot tolerate oral liquids for prolonged periods or who are clinically dehydrated, intravenous hydration that includes dextrose is recommended. Due to potential maternal complications, enteral therapy is preferred over parenteral if nutrition support is required. Parenteral nutrition (which may include dextrose) should be reserved for use in patients with severe nausea and vomiting not responsive to enteral therapy (ACOG 189 2018). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant patient. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Oral dextrose is used for the screening and diagnosis of gestational diabetes mellitus in pregnant patients not previously diagnosed with diabetes (ADA 2023).</p></div>
<div class="block brc drugH1Div" id="F51427261"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Glucose is endogenous to breast milk (IOM 2005).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block dic drugH1Div" id="F9835684"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;">Some products may contain potassium and/or sodium.</p></div>
<div class="block mop drugH1Div" id="F158893"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood glucose, serum electrolytes, fluid status, caloric intake, acid-base balance, infusion site.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Calcium channel blocker or beta-blocker overdose/toxicity</i>: Monitor blood glucose concentrations every 10 minutes at the initiation and titration of high-dose insulin therapy and adjunctive dextrose. Decrease frequency of monitoring to every 30 to 60 minutes once insulin dose is stable (Engebretsen 2011).</p></div>
<div class="block rer drugH1Div" id="F158896"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL; hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL; threshold for neuroglycopenic symptoms; requires immediate action</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Glucose tolerance test (diagnostic criteria) (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">One step (75 g dose [fasting]):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Non-pregnant adults: </i>Plasma glucose ≥200 mg/dL at 2 hours post-dose meets diagnostic criteria for diabetes; diagnosis requires two abnormal test results from the same sample or in two separate test samples (using the same or different tests) unless there is a clear clinical diagnosis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pregnant adults: </i>Any of the following plasma glucose levels meet diagnostic criteria for gestational diabetes: Fasting: ≥92 mg/dL; 1 hour post-dose: ≥180 mg/dL; 2 hours post-dose: ≥153 mg/dL.</p>
<p style="text-indent:-2em;margin-left:4em;">Two-step (first dose: 50 g [nonfasting]; second dose: 100 g [fasting]): Pregnant adults:</p>
<p style="text-indent:-2em;margin-left:6em;">First step (50 g dose): If plasma glucose levels ≥130 mg/dL at 1 hour post-dose, proceed to 100 g oral glucose tolerance test. <b>Note:</b> Cutoffs of ≥135 or ≥140 mg/dL have also been recommended; increased sensitivity and decreased specificity have been associated with use of a lower cutoff.</p>
<p style="text-indent:-2em;margin-left:6em;">Second step (100 g dose): 2 or more of the following plasma glucose levels meet diagnostic criteria for gestational diabetes: Fasting ≥95 mg/dL; 1 hour post-dose: ≥180 mg/dL; 2 hours post-dose: ≥155 mg/dL; 3 hours post-dose: ≥140 mg/dL</p></div>
<div class="block pha drugH1Div" id="F158886"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dextrose, a monosaccharide, is a source of calories and fluid for patients unable to obtain an adequate oral intake; may decrease body protein and nitrogen losses; promotes glycogen deposition in the liver. When used in the treatment of hyperkalemia (combined with insulin), dextrose stimulates the transient uptake of potassium by cells, especially in muscle tissue, lowering serum potassium.</p></div>
<div class="block phk drugH1Div" id="F158900"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Treatment of hypoglycemia: Oral: 10 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Maximum effect: Treatment of hyperkalemia: IV: 30 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapidly from the small intestine by an active mechanism; Buccal: negligible (Gunning 1978)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized to carbon dioxide and water</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 40 minutes</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F158903"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dextrose</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Soluc. dextrosa isotonica | Soluc. glucosada hipertonica | Solucion de dextrosa | Solucion de dextrosa norgreen | Solucion dextrosa jayor</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Glucose Baxter | Glucose Braun | Glucose Fresenius Kabi | Glucose mayrhofer | Traubenzucker fresenius kabi</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | TRUEplus glucose</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Acme's dextrose | Acme's dextrose ds | Dexaqua | Dexoride | Dextropac | Dextrose | Dextrose water | Libott | Libott s junior | Neosol | Nutridex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Gluc10% baxter | Glucose 10% baxter | Glucose 10% braun | Glucose 10% braun pharma | Glucose 15% clintec benelux | Glucose 20% braun | Glucose 20% braun pharma | Glucose 30% baxter | Glucose 30% braun | Glucose 30% braun pharma | Glucose 40% clintec benelux | Glucose 5% braun | Glucose 5% braun pharma | Glucose 50% baxter | Glucose 50% braun | Glucose 50% braun pharma | Glucose Baxter | Glucose sterop</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Glucose b braun | Glucose intravenous</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dextrosa | Dextrose | Glucose Biopharm</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Baxter glicose | Farmace glicose 5% solucao isotonica | Glicofisiologica | Glicosado | Glicose | Glicose beker | Glicose halex istar | Glicose hipertonica | Glicose monoidratada | Jp glicose | Sol glic.fisiolog. | Sol glic.isotonico | Solucao de glicose | Solucao de glicose b. braun | Solucao de glicose hipertonica | Solucao de glicose isotonica | Soro glico cloreta | Soro glico fisiolo | Soro glicosado isotonico</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Glucose Amino | Glucose B. Braun | Glucose Baxter</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Axadex | Axadex dns</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Glucosa</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Dextrosa | Dextrosa agua | Dextrosa al | Dextrovit | Dx 5 | Glucoquick | Solucion Dx 10 | Solucion dx 5</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Ardeanutrisol g | Ardeanutrisol g 33 | Ardeanutrisol gsp | Dextrose | Glucosa | Glucose losung | Glucosum | Glucosum spofa | Infusio f 1/2 | Infusio glucosi | Viaflo Glucose</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dextromed | Glucose demo | Glucose loesung | Glucose loesung 50 % deltamedica | Glucose loesung deltaselect | Glucoseloesung | Traubenzucker</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dextrosa | Dextrosa en agua | Indodextro</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dextrosa | Dextrosa en agua | Glucosa</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Glikozes | Glucos | Glucosa | Glucose Braun | Glucose fresenius | Glucose groteks | Glucosi | Glucosteril | Glucosum | Glucosum physioneal | Natrosteril-3 | Solutio glucosi</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Dextrose water</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Apir glucosado isotonico | Apiroflex glucosada | Dextrosa braun | Dextrosa fresenius | Dextrosa pharmacia | Flebobag glucosada grifols | Freeflex glucosa | Glucocemin | Glucosa baxter | Glucosa biomendi | Glucosa braun | Glucosa ife | Glucosa mein | Glucosa physan | Glucosa tecsolpar | Glucosada fresenius | Glucosada Grifols | Glucosado bieffe | Glucosado vitulia | Glucosmon | Glucosmon r50 | Meinvenil glucosa | Venofusin glucosa</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">5d</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Glucos | Glucos b.braun | Glucos baxter | Glucosteril</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Glucose aguettant | Glucose b braun | Glucose Baxter | Glucose bieffe | Glucose bioluz | Glucose biosedra | Glucose cooper | Glucose elbiol | Glucose fandre | Glucose fresenius | Glucose lavoisier | Glucose macopharma | Glucose Renaudin | Hydros g5 | Hypostop</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Braun glucose | Dextrogel | Dextrose | Easyflex n glucose | Glucogel | Glucose intravenous | Ims dextrose | Intravenous dextrose | Polyfusor dextrose | Trav dextrose</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Dextrose injection/bradex | Dextrose water</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dextrose</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Glukoza | Glukoza braun</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Glucosi | Glucosio Monico | Glucosum-pannonpharma | Glukoz | Glukoz bieffe | Glukoz teva | Invertosol 10 | Isodex | Szorbit</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Fima D5 | Glucosum | Infusan D10 | Infusan D5 | Ka-en 1b | Tridex Plain | Viaflex dextrose</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Braun dextrose | Dextrose</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Dextrose</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Hydrofast-22 | Hydrofast-33 | Hydrofast-45 | Hypotab | Levodex-s | Premodex</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Dextrose</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Glucosio | Glucosio B. Braun</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Dextrose</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Gluco b | Glucose afp | Glucose ajinomoto | Glucose amel | Glucose arax | Glucose boehringer | Glucose chemix | Glucose chugai | Glucose daiichi | Glucose hikari | Glucose isei | Glucose kobayashi | Glucose kyorin | Glucose kyosei | Glucose merck hoei | Glucose mohan | Glucose mp sawai | Glucose nichiiko | Glucose nipro | Glucose otsuka | Glucose sanko | Glucose sn | Glucose t | Glucose teisan | Glucose terumo | Glucose towa | Glunon fuso | Lodinon | Nahron</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">5d | Axadex d5 | D10 | D5 | Dextrose | Infusol D5</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Braun glucose | Daihan dextrose | Dextrose | Dextrose bax | Dextrose injection 20% huons | Dextrose jeil | Huons glucose | Inno.n 10% dextrose | Inno.n 20% dextrose | Inno.n 5% dextrose | Inno.n 50% dextrose | Jw 10% dextrose | Jw 15% dextrose | Jw 20% glucose | Jw 30% glucose | Jw 5% glucose | Jw 70% dextrose | Normodex | One four | One three | One two | Uk dextrose</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Glucose Renaudin | Serum dextrose</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Glucose Baxter | Glucosi | Glucosum</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Glucosteril</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Glucosum</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Glucose laprophan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dc6 claire | Delmed six | Dex4 | Dextrabbott | Dextralpha | Dextrosa | Dextrosa al | Kabidecs | Solucion dextrosa baxter | Solucion dextrosa pisa | Solucion dx 5 pisa | Solucion dx-cs</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Infusol D10 | Infusol D20 | Infusol D5 | Infusol D50</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">5% dextrose infusion | Bioflex dextrose | Dextrose | Drugfield Dextrose | Juhel dextrose | Unidex</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Glucosum</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Glucos | Glucos baxter viaflo | Glucose Fresenius Kabi | Glucotabs | Glukos Fresenius kabi | Glukose</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bio organics glycemix glucose rapid | Biomed dextrose | Biomed glucose | Dextrose</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dextro lusa | Dextrosa | Dextrosa agua | Soludex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Endure Medical Dextrose in Water</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Aquasol | Aquasol s | Batalasol | Dexsol | Dextrose water | Immuasol | Immunasol | Istrose | Lifesol s | Lifesol water | Macsol | Medisol | Neustore 10 | Neustore 5 | Paksol dextrose | Pladex | Revasol | Searle 10% | Searle 5% | Solvein ds | Solvein water | Steriflex dw | Zeesol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Glucosteril | Glucosum</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Glutose</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Glucosada Grifols | Glucosado | Glucosado Braun | Glucose Basi | Glucose Braun | Glucose fresenius | Glucose Labesfal | Glucose paracelsia | Glucose Viaflo | Glucosteril | Soro Glucosado | Soro Glucosado B.Braun | Soro Glucosado Isotonico | Viaflex Glucose | Viaflo Glucose</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dextrosa 5% bergamo | Dextrosa 5% prosalud | Dextrosa demotek | Glucosa 10 % vioser | Glucosa 5 % vioser | Glucosa 5% imh | Glucosa 5% medicine | Glucosa 5% sanderson | Glucosa hipertonica sanderson | Glucosa sanderson | Solucion dextrosa al baxter | Solucion dextrosa baxter | Solucion dextrosa hipertonica | Solucion dextrosa index | Solucion glucofisiologica diproan | Solucion glucosada hipertonica catedral | Solucion hipertonica de glucosa b braun | Solucion isotonica de dextrosa roux ocefa | Solucion isotonica de glucosa | Suero glucosado hipertonico fusa | Suero glucosado isotonico fusa | Suero glucosado isotonico fusa np</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Ansyr II | Fluidex | Insta-Glucose | Microdot | Rapilose | Transcend</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dextrose vioser | Glucose b braun | Glucosteril</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Glucose bufus | Glucose solopharm | Glucose vial | Glucosteril | Lycadex PF dextrose monohydrate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dextrose</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Glucos b.braun | Glucos baxter | Glucos baxter viaflo | Glucos fresenius kabi | Glukos Fresenius kabi</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Gluco 4</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Glucosi | Glucosum | Glukosa | Glukoza | Glukoza Baxter | Glukoza Pliva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Glucose B P Bieffe | Glucosum | Infusio glucosi</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">5d | Dextrose</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Dextrosol | Umeda glucose</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Glucose Fresenius Kabi | Serum glucose</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dekstroz | Dextrose | Dextrose mediflex | Glucotabs | Kanfleks dekstroz | Lafleks dekstroz | Neofleks dekstroz | Pro fleks dekstroz | Turkfleks dekstroz</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bluton | Deose | Dextrose | Ditrose | Electrose | Fulin | Gitose | Suntose | Vitagen</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Gastrovitol | Glucose Cytoclin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">5d | D10 | D5 | D50</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dextrosa | Suero glucosado | Suero Glucosado Hipertonico | Suero Glucosado Isotonico</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Dextrosa | Dextrosa agua</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco-dextrose | Autosterile glucos | Dex4 | Dextrose | Dextrose forrester | Dextrose in water | Glucose b braun | Sabax glucose</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Dextrose</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Dextrose | Dextrose fresenius</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-36537534">
<a name="36537534"></a>Abraham MB, Karges B, Dovc K, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes. <i>Pediatr Diabetes</i>. 2022;23(8):1322-1340. doi:10.1111/pedi.13443<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/36537534/pubmed" id="36537534" target="_blank">36537534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21357346">
<a name="21357346"></a>Adamkin DH and Committee on Fetus and Newborn. Postnatal Glucose Homeostasis in Late-Preterm and Term Infants. <i>Pediatrics</i>. 2011;127(3):575-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/21357346/pubmed" id="21357346" target="_blank">21357346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27605513">
<a name="27605513"></a>Adamkin DH. Neonatal hypoglycemia. <i>Semin Fetal Neonatal Med</i>. 2017;22(1):36-41. doi:10.1016/j.siny.2016.08.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/27605513/pubmed" id="27605513" target="_blank">27605513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10816188">
<a name="10816188"></a>Adrogué HJ, Madias NE. Hypernatremia. <i>N Engl J Med</i>. 2000;342(20):1493-1499. doi:10.1056/NEJM200005183422006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/10816188/pubmed" id="10816188" target="_blank">10816188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2266671">
<a name="2266671"></a>Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. <i>Kidney Int</i>. 1990;38(5):869-872. doi:10.1038/ki.1990.284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/2266671/pubmed" id="2266671" target="_blank">2266671</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aluminum.1">
<a name="Aluminum.1"></a>Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30. doi:10.1097/AOG.0000000000002456<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.3">
<a name="ADA.3"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023.<i> Diabetes Care.</i> 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed May 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASPEN.2">
<a name="ASPEN.2"></a>American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. https://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/PN%20Dosing%201-Sheet-Nov%202020-FINAL.pdf. Updated November 17, 2020. Accessed May 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASPEN.1">
<a name="ASPEN.1"></a>ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients. <i>JPEN J Parenter Enteral Nutr</i>. 2002;26(1)(suppl):1-138.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barrero-Castillero.1">
<a name="Barrero-Castillero.1"></a>Barrero-Castillero A, Simmons R. Hypoglycemia and hyperglycemia. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams &amp; Wilkins; 2022: chap. 24.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Barrueto.1">
<a name="Barrueto.1"></a>Barrueto F. Calcium channel blocker poisoning. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 30, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30093549">
<a name="30093549"></a>Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. <i>Diabetes Care</i>. 2018;41(9):2026-2044.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/30093549/pubmed" id="30093549" target="_blank">30093549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29452919">
<a name="29452919"></a>Cole JB, Arens AM, Laes JR, Klein LR, Bangh SA, Olives TD. High dose insulin for beta-blocker and calcium channel-blocker poisoning. <i>Am J Emerg Med</i>. 2018;36(10):1817-1824. doi:10.1016/j.ajem.2018.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/29452919/pubmed" id="29452919" target="_blank">29452919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corkins.1">
<a name="Corkins.1"></a>Corkins MR, Balint J, Bobo E, Plogsted S, Yaworski, JA, eds. <i>The</i> A<i>.S.P.E.N. Pediatric Nutrition Support Core Curriculum</i>. 2nd ed. American Society for Parenteral and Enteral Nutrition; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24139581">
<a name="24139581"></a>Daly K, Farrington E. Hypokalemia and hyperkalemia in infants and children: pathophysiology and treatment. <i>J Pediatr Health Care</i>. 2013;27(6):486-498. doi:10.1016/j.pedhc.2013.08.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/24139581/pubmed" id="24139581" target="_blank">24139581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30973639">
<a name="30973639"></a>De Buck E, Borra V, Carlson JN, Zideman DA, Singletary EM, Djärv T. First aid glucose administration routes for symptomatic hypoglycaemia (review). <i>Cochrane Database Syst Rev</i>. 2019;4(4):CD013283. doi:10.1002/14651858.CD013283.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/30973639/pubmed" id="30973639" target="_blank">30973639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25905360">
<a name="25905360"></a>Desimone ME, Weinstock RS. Hypoglycemia. In: Feingold KR, Anawalt B, Boyce A, et al, eds. <i>Endotext</i>. MDText.com Inc; 2000. <a href="https://www.ncbi.nlm.nih.gov/books/NBK279137" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK279137</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/25905360/pubmed" id="25905360" target="_blank">25905360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dex4.1">
<a name="Dex4.1"></a>Dex4 (dextrose) [prescribing information]. Allegan MI: Perrigo; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dex4.2">
<a name="Dex4.2"></a>Dex4 liquid (dextrose) [prescribing information]. Allegan MI: Perrigo; 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.1">
<a name="Dextrose.1"></a>Dextrose 5% injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.13">
<a name="Dextrose.13"></a>Dextrose 5% injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.2">
<a name="Dextrose.2"></a>Dextrose 5% injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.3">
<a name="Dextrose.3"></a>Dextrose 5% and 10% injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.10">
<a name="Dextrose.10"></a>Dextrose 10% injection [prescribing information]. Franklin Lakes, NJ: Becton, Dickinson and Company; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.4">
<a name="Dextrose.4"></a>Dextrose 10% injection [prescribing information]. Lake Forest, IL: Hospira Inc; June 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.5">
<a name="Dextrose.5"></a>Dextrose 20%, 30%, 40%, 50%, and 70% injection [prescribing information]. Lake Forest, IL: Hospira Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.6">
<a name="Dextrose.6"></a>Dextrose 25% injection [prescribing information]. Lake Forest, IL: Hospira Inc; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.11">
<a name="Dextrose.11"></a>Dextrose 25% injection [prescribing information]. Lake Forest, IL: Hospira Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.12">
<a name="Dextrose.12"></a>Dextrose 50% injection [prescribing information]. Lake Forest, IL: Hospira Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.7">
<a name="Dextrose.7"></a>Dextrose 50% injection [prescribing information]. South El Monte, CA: International Medication Systems Ltd; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.8">
<a name="Dextrose.8"></a>Dextrose 70% injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dextrose.9">
<a name="Dextrose.9"></a>Dextrose injection in Viaflex plastic container [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35302645">
<a name="35302645"></a>Edwards T, Liu G, Battin M, et al. Oral dextrose gel for the treatment of hypoglycaemia in newborn infants. <i>Cochrane Database Syst Rev</i>. 2022;3(3):CD011027. doi:10.1002/14651858.CD011027.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/35302645/pubmed" id="35302645" target="_blank">35302645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20855477">
<a name="20855477"></a>Elliott MJ, Ronksley PE, Clase CM, Ahmed SB, Hemmelgarn BR. Management of patients with acute hyperkalemia. <i>CMAJ</i>. 2010;182(15):1631-1635.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/20855477/pubmed" id="20855477" target="_blank">20855477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21563902">
<a name="21563902"></a>Engebretsen KM, Kaczmarek KM, Morgan J, Holger JS. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. <i>Clin Toxicol (Phila)</i>. 2011;49(4):277-283. doi:10.3109/15563650.2011.582471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/21563902/pubmed" id="21563902" target="_blank">21563902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Garg.1">
<a name="Garg.1"></a>Garg M, Devaskar SU. Disorders of carbohydrate metabolism in the neonate. In: Martin RJ, Fanaroff AA, Walsh MC, eds. <i>Fanaroff and Martin's Neonatal-Perinatal Medicine</i>. 11th ed. Elsevier; 2020: chap. 86.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glucose.1">
<a name="Glucose.1"></a>Glucose tablets (dextrose) [prescribing information]. Livonia, MI: Rugby Laboratories; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glutol.1">
<a name="Glutol.1"></a>Glutol (dextrose) [prescribing information]. Minneapolis, MN: Perrigo; February 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glutose.1">
<a name="Glutose.1"></a>Glutose 15 (dextrose) [prescribing information]. Minneapolis, MN: Padagis; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-691147">
<a name="691147"></a>Gunning RR, Garber AJ. Bioactivity of instant glucose. Failure of absorption through oral mucosa. <i>JAMA</i>. 1978;240(15):1611-1612.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/691147/pubmed" id="691147" target="_blank">691147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17667395">
<a name="17667395"></a>Hadaway L. Infiltration and extravasation. <i>Am J Nurs</i>. 2007;107(8):64-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/17667395/pubmed" id="17667395" target="_blank">17667395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33507929">
<a name="33507929"></a>Harding JE, Hegarty JE, Crowther CA, et al. Evaluation of oral dextrose gel for prevention of neonatal hypoglycemia (hPOD): a multicenter, double-blind randomized controlled trial. <i>PLoS Med</i>. 2021;18(1):e1003411. doi:10.1371/journal.pmed.1003411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/33507929/pubmed" id="33507929" target="_blank">33507929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26613985">
<a name="26613985"></a>Harris DL, Alsweiler JM, Ansell JM, et al. Outcome at 2 years after dextrose gel treatment for neonatal hypoglycemia: follow-up of a randomized trial. <i>J Pediatr</i>. 2016;170:54-9.e92. doi:10.1016/j.jpeds.2015.10.066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/26613985/pubmed" id="26613985" target="_blank">26613985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24075361">
<a name="24075361"></a>Harris DL, Weston PJ, Signal M, Chase JG, Harding JE. Dextrose gel for neonatal hypoglycaemia (the Sugar Babies Study): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i>. 2013;382(9910):2077-2083.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/24075361/pubmed" id="24075361" target="_blank">24075361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-InfantDextrose.1">
<a name="InfantDextrose.1"></a>Infant Dextrose 25% (dextrose) [prescribing information]. Lake Forest, IL: Hospira Inc; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice. Plain D<sub>5</sub>W or Hypotonic Saline Solutions Post-Op Could Result in Acute Hyponatremia and Death in Healthy Children. <i>ISMP Medication Safety Alert</i>. August 13, 2009. http://www.ismp.org/Newsletters/acutecare/articles/20090813.asp
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>Institute of Medicine (IOM). Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). Washington, D.C.: The National Academies Press; 2005. <a href="https://www.nap.edu/catalog/10490/dietary-reference-intakes-for-energy-carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino-acids" target="_blank">https://www.nap.edu/catalog/10490/dietary-reference-intakes-for-energy-carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino-acids</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23164767">
<a name="23164767"></a>Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the Use of an Insulin Infusion for the Management of Hyperglycemia in Critically Ill Patients. <i>Crit Care Med</i>. 2012;40(12):3251-3276.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/23164767/pubmed" id="23164767" target="_blank">23164767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi:10.1161/CIR.0000000000000300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1737458">
<a name="1737458"></a>Khilnani P. Electrolyte abnormalities in critically ill children. <i>Crit Care Med</i>. 1992;20(2):241-250.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/1737458/pubmed" id="1737458" target="_blank">1737458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16085929">
<a name="16085929"></a>Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. <i>Am J Health Syst Pharm</i>. 2005;62(16):1663-1682. doi:10.2146/ajhp040300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/16085929/pubmed" id="16085929" target="_blank">16085929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30141827">
<a name="30141827"></a>Krenz JR, Kaakeh Y. An Overview of hyperinsulinemic-euglycemic therapy in calcium channel blocker and β-blocker overdose. <i>Pharmacotherapy</i>. 2018;38(11):1130-1142. doi:10.1002/phar.2177<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/30141827/pubmed" id="30141827" target="_blank">30141827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412709">
<a name="30412709"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2019;74(7):e51-e156. doi:10.1016/j.jacc.2018.10.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/30412709/pubmed" id="30412709" target="_blank">30412709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3302901">
<a name="3302901"></a>LaFranchi S. Hypoglycemia of infancy and childhood. <i>Pediatr Clin North Am</i>. 1987;34(4):961-982.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/3302901/pubmed" id="3302901" target="_blank">3302901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24714850">
<a name="24714850"></a>Le A, Patel S. Extravasation of noncytotoxic drugs: a review of the literature. <i>Ann Pharmacother</i>. 2014;48(7):870-886.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/24714850/pubmed" id="24714850" target="_blank">24714850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21181208">
<a name="21181208"></a>Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. <i>Pediatr Nephrol</i>. 2011;26(3):377-384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/21181208/pubmed" id="21181208" target="_blank">21181208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36537527">
<a name="36537527"></a>Libman I, Haynes A, Lyons S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Definition, epidemiology, and classification of diabetes in children and adolescents. <i>Pediatr Diabetes</i>. 2022;23(8):1160-1174. doi:10.1111/pedi.13454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/36537527/pubmed" id="36537527" target="_blank">36537527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22762930">
<a name="22762930"></a>Lindner G, Funk GC. Hypernatremia in critically ill patients. <i>J Crit Care</i>. 2013;28(2):216.e11-e20. doi:10.1016/j.jcrc.2012.05.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/22762930/pubmed" id="22762930" target="_blank">22762930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7400902">
<a name="7400902"></a>Lilien LD, Pildes RS, Srinivasan G, Voora S, Yeh TF. Treatment of neonatal hypoglycemia with minibolus and intravenous glucose infusion. <i>J Pediatr</i>. 1980;97(2):295-298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/7400902/pubmed" id="7400902" target="_blank">7400902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lynch.1">
<a name="Lynch.1"></a>Lynch R, Wood EG, Neumayr TM. Fluid and electrolyte issues in pediatric critical illness. In: Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier; 2016:chap. 73.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation - A Hazard of Intravenous Therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21920871">
<a name="21920871"></a>Masilamani K, van der Voort J. The management of acute hyperkalaemia in neonates and children. <i>Arch Dis Child</i>. 2012;97(4):376-380.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/21920871/pubmed" id="21920871" target="_blank">21920871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8642888">
<a name="8642888"></a>McMahon MM, Rizza RA. Nutrition support in hospitalized patients with diabetes mellitus. <i>Mayo Clin Proc</i>. 1996;71(6):587-594. doi:10.4065/71.6.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/8642888/pubmed" id="8642888" target="_blank">8642888</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568296">
<a name="15568296"></a>Mirtallo J, Canada T, Johnson D, et al. Safe Practices for Parenteral Nutrition. <i>JPEN J Parenter Enteral Nutr.</i> 2004;28(6):S39-S70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/15568296/pubmed" id="15568296" target="_blank">15568296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31084947">
<a name="31084947"></a>Moussavi K, Fitter S, Gabrielson SW, Koyfman A, Long B. Management of hyperkalemia with insulin and glucose: pearls for the emergency clinician. <i>J Emerg Med</i>. 2019;57(1):36-42. doi:10.1016/j.jemermed.2019.03.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/31084947/pubmed" id="31084947" target="_blank">31084947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31844395">
<a name="31844395"></a>Narvey MR, Marks SD. The screening and management of newborns at risk for low blood glucose. <i>Paediatr Child Health</i>. 2019;24(8):536-554. doi:10.1093/pch/pxz134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/31844395/pubmed" id="31844395" target="_blank">31844395</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult basic and advanced life support writing group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Polin.1">
<a name="Polin.1"></a>Polin RA, Adamkin DH. Glucose, calcium, and magnesium. In: Fanaroff AA, Fanaroff JM, eds. <i>Klaus and Fanaroff's Care of the High-Risk Neonate</i>. 7th ed. Elsevier; 2020: chap. 11.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30728169">
<a name="30728169"></a>Qian Q. Hypernatremia. <i>Clin J Am Soc Nephrol</i>. 2019;14(3):432-434. doi:10.2215/CJN.12141018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/30728169/pubmed" id="30728169" target="_blank">30728169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rajajee.1">
<a name="Rajajee.1"></a>Rajajee V. Management of acute moderate and severe traumatic brain injury. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sterns.1">
<a name="Sterns.1"></a>Sterns RH, Hoorn EJ. Treatment of hypernatremia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24052783">
<a name="24052783"></a>Sweet CB, Grayson S, Polak M. Management strategies for neonatal hypoglycemia. <i>J Pediatr Pharmacol Ther</i>. 2013;18(3):199-208. doi:10.5863/1551-6776-18.3.199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/24052783/pubmed" id="24052783" target="_blank">24052783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25957977">
<a name="25957977"></a>Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children. <i>J Pediatr</i>. 2015;167(2):238-245. doi:10.1016/j.jpeds.2015.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/25957977/pubmed" id="25957977" target="_blank">25957977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care [published corrections appear in <i>Circulation</i>. 2011;123(6):e239 and <i>Circulation</i>. 2011;124(15):e405]. <i>Circulation</i>. 2010;122(18)(suppl 3):s829-s861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Whitesel.1">
<a name="Whitesel.1"></a>Whitesel E. Fluid and electrolyte management. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR, eds. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Lippincott Williams &amp; Wilkins; 2022: chap. 23.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20159411">
<a name="20159411"></a>Wiegand R, Brown J. Hyaluronidase for the management of dextrose extravasation. <i>Am J Emerg Med</i>. 2010;28(2):257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/instant-glucose-and-intravenous-dextrose-drug-information/abstract-text/20159411/pubmed" id="20159411" target="_blank">20159411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilkins.1">
<a name="Wilkins.1"></a>Wilkins B, Hazell W. Disorders of fluids, electrolytes and acid-base. In: Cameron P, Jelinek G, Everitt I, Browne G, Raftos J, eds. <i>Textbook of Paediatric Emergency Medicine</i>. 2nd ed. Churchill Livingstone; 2011:chap. 10.5.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1">
<a name="Zenk.1"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8711 Version 542.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
